Keywords:
Lymphoblastic leukemia; B-cell acute lymphoblastic leukemia; Down Syndrome; preclinical cohort
Abstract:
Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL).